Chinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial

Phase 3

Not yet recruiting

• Conditions: Intracerebral Hemorrhage
• Interventions: Drug: Chinese herbal medicine FYTF-919

• Registration Number: NCT05066620
• Lead Sponsor: Guangzhou University of Traditional Chinese Medicine

Brief Summary

TCM is an essential context of the ICH management in Chinese culture. Given the potential benefits of Chinese herbal medicine FYTF-919 in reducing haematoma and bleeding after acute ICH from fundamental research and small clinical studies, more reliable evidence is required to guide ICH treatment using TCM. This study aims to determine the effectiveness and safety of TCM in a larger sample of patients with moderate-severe ICH and provide evidence for TCM clinical guidelines on ICH management. The presumed mechanism of action is in promoting the reabsorption of the haematoma and perihematomal oedema in ICH.

Detailed Description

A multicentre, prospective, randomised, double-blind, placebo-controlled trial to be conducted through hospital network of investigators in China. A total of 1504 patients with ICH will be recruited from approximately 20-30 hospitals. Randomised is via a central internet-based system according to block random grouping method stratified by site, neurological severity NIHSS \<15 vs ≥15), and haematoma location (basal ganglia + lobe vs thalamus + cerebellum + brain stem + ventricle) to ensure balance in key prognostic factors. Endpoint assessment will be blinded to treatment allocation. The primary aim of this study is to determine the effectiveness and safety of a Chinese herbal medicine FYTF-919 as compared to placebo on functional recovery according to Utility-weighted modified Rankin scale (UW-mRS) at 90 days after acute ICH. Secondary aims include examining whether the Chinese herbal medicine FYTF-919 leads to positive treatment effect on: 1) Utility-weighted mRS scores at 180 days; 2)Ordinal analysis of 7 levels of mRS at 28 days, 90 days and 180 days; 3) Poor prognosis, defined as mRS 4-6 points at 28 days, 90 days and 180 days; 4) NIHSS score at 7 days and 28 days; 5) Mortality rate at 28 days, 90 days and 180 days; 6) Discharge rate at 28 days; 7) EQ-5D-5L at 28days, 90 days and 180 days; 8) BI at 28 days, 90 days and 180 days; 9) The cerebral edema volume at baseline, 24 hours, 7 days, 14 days or at discharge; 10) The hematoma volume at baseline, 24 hours, 7 days, 14 days or discharge; 11) The incidence of stroke-associated pneumonia (SAP) patients; 12) Clinical pulmonary infection score (CIPS) at the onset of SAP, 3 days, and 7 days, after the occurrence of SAP; 13) Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture at the onset of SAP, 3 days, and 7 days after the occurrence of SAP; 14) Antibiotic usage among patients with SAP.

Study Timeline

• Status Verified: 2021-09
• Study First Submitted: 2021-09-07
• Study First Submitted QC: 2021-09-24
• Last Update Submitted: 2021-09-24
• Study Start: 2021-10
• Study First Posted: 2021-10-04
• Last Update Posted: 2021-10-04
• Primary Completion: 2024-12
• Study Completion: 2025-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 1504

Inclusion Criteria

1. Age ≥18 years;
2. Diagnosis of spontaneous ICH, confirmed by brain imaging;
3. Presentation within 48 hours of symptom onset (or last seen well);
4. Meet any of the following criteria: a) NIHSS ≥8, or b) GCS 7-14;
5. Provide written informed consent by patient (or approved surrogate);

Exclusion Criteria

1. ICH secondary to a structural abnormality in the brain (e.g. cerebrovascular malformation, arterial aneurysm, tumour, Moyamoya disease, trauma, or previous ischaemic stroke), or secondary to presumed cerebrovascular amyloidosis, or secondary to reperfusion treatment for ischaemic stroke, or secondary to anticoagulant treatment, or secondary to antiplatelet treatment.
2. Unlikely to potentially benefit from therapy (e.g. advanced dementia) or judged by responsible treating clinician to have a high likelihood of early death irrespective of treatment;
3. Other medical illness that will interfere with outcome assessments and follow-up (e.g. known significant pre-stroke disability [modified Rankin scale {mRS} scores 4-5], advanced cancer and renal failure);
4. Known definite contraindication to the Chinese herbal medicine;
5. Women who are known to be pregnant or lactating;
6. Currently participating in another trial which would interfere with outcome assessments.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention group	Chinese herbal medicine FYTF-919	Chinese herbal medicine FYTF-919: Oral liquid 33ml TID (for patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)
Control group	Chinese herbal medicine FYTF-919	Placebo treatment: Oral liquid 33ml TID (or patients who are unconscious or dysphagia, a dose of 25ml \* Q6H will be given through nasal feeding)

Primary Outcome Measures

Name	Time	Method
Utility-weighted modified Rankin scale scores	90 days after the treatment started	Utility-weighted modified Rankin scale scores. The value range from 0 to 10: higher scores mean a better outcome.

Secondary Outcome Measures

Name	Time	Method
Utility-weighted mRS scores	180 days after the treatment started	Utility-weighted modified Rankin scale scores. The value range from 0 to 10: higher scores mean a better outcome.
Poor prognosis rate	28 days, 90 days and 180 days after the treatment started	Binary variable: 1 means mRS 4-6 points; 0 means mRS is 0-3 points.
NIHSS score	7 days and 28 days after the treatment started	National Institute of Health Stroke Scale Score. The value range 0-42: higher scores mean a worse outcome.
Discharge rate	28 days after the treatment started	Discharge rate
BI	28 days, 90 days and 180 days after the treatment started	Barthel index. The value range 0-100: higher scores mean a better outcome.
Antibiotic usage	The onset of SAP, 3 days and 7 days after the occurrence of SAP	Antibiotic usage among patients with SAP
The cerebral edema volume	Baseline, 24 hours, 7 days, 14 days or at discharge	The cerebral edema volume
SAP	Baseline, 24 hours, 7 days, 14 days or discharge	The incidence of stroke-associated pneumonia patients
Pulmonary infection	The onset of SAP, 3 days and 7 days after the occurrence of SAP	Diagnosed by using the Chest imaging (DR/CT), body temperature, white blood cell count, C-reactive protein (CRP), procalcitonin (PCT) blood gas analysis, and sputum culture/airway aspirate culture
Mortality rate	28 days, 90 days and 180 days	Mortality rate
7 levels of mRS	28 days, 90 days and 180 days after the treatment started	Ordinal analysis of 7 levels of mRS. The value range 0-6: higher scores mean a worse outcome.
The hematoma volume	Baseline, 24 hours, 7 days, 14 days or discharge	The hematoma volume
CPIS	The onset of SAP, 3 days and 7 days after the occurrence of SAP	Clinical pulmonary infection score. The value range 0-12: higher scores mean a worse outcome.
European Quality of Life 5-dimensional questionnaire (EQ-5D-5L)	28 days, 90 days and 180 days after the treatment started	The EQ-5D comprises five dimensions of health: mobility, ability to self-care, ability to undertake usual activities, pain and discomfort, and anxiety and depression. . EQ-5D-5L, includes five levels of severity for each dimension (no problems, slight problems, moderate problems, severe problems, and extreme problems). The value range 0-100: higher scores mean a worse outcome.

Trial Locations

Locations (1)

Guangdong Provincial Hospital of Chinese Medicine; 🇨🇳 Guangzhou, Guangdong, China